Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial.
Masanori KatoHidetoshi ItoAkane YamakawaTatsuo KagimuraMasafumi FukagawaMasahiro YamamotoYoshinori SaitoTadao AkizawaHiroaki OgataPublished in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2024)
Aspirin use was not significantly associated with a lower risk of CVEs in participants undergoing hemodialysis patients at risk of vascular calcification.
Keyphrases
- cardiovascular events
- chronic kidney disease
- end stage renal disease
- patients undergoing
- coronary artery disease
- peritoneal dialysis
- cardiovascular disease
- clinical trial
- study protocol
- phase iii
- low dose
- phase ii
- type diabetes
- percutaneous coronary intervention
- acute coronary syndrome
- atrial fibrillation
- antiplatelet therapy
- placebo controlled